🧬 Immunology Updates: Policy shifts in IBD drug access, breakthrough results in Crohn’s disease and ulcerative colitis, pipeline progress in autoimmune conditions and more!
From regulatory developments to late-stage trial wins and high-value partnerships, these updates are shaping the future of autoimmune and inflammatory disease management. Let’s dive into the most impactful stories in immunology this week.
Here’s what you need to know ⬇️
🇰🇷 Drug pricing policy concerns in Korea — IBD cases up 30 percent in five years, with younger patients increasingly affected. Experts warn that U.S. “Most-Favored-Nation” pricing reforms could limit access to new IBD therapies in Korea.
🧬 Avobis Bio’s AVB-114 for Crohn’s perianal fistulas — Phase II STOMP-II trial met goals, leading to a request for Regenerative Medicine Advanced Therapy designation and expedited Phase III discussions with the FDA.
💊 PALI-2108 hits 100 percent clinical response in ulcerative colitis — In Phase 1b, all patients achieved at least a 30 percent symptom reduction with strong biomarker improvements. Phase 2 IND filing planned for the first half of 2026.
📈 Anaptys’ autoimmune pipeline progress — Rosnilimab shows strong efficacy and durability in Phase 2b rheumatoid arthritis. Phase 2 ulcerative colitis trial fully enrolled with data expected Q4 2025. ANB033 set to enter Phase 1b in celiac disease by year-end 2025.
🤖 Almirall and Absci expand AI partnership in dermatology — Second dermatology target added after success with the first AI-designed antibody program. Deal value up to 650 million dollars plus royalties.
📚 EAACI launches EAACI Nexus — A Netflix-style global education platform for allergy and immunology professionals, centralizing congress content, webinars, and guidelines.
🇨🇦 Kolon Life Science secures Canadian patent for TG-C — Osteoarthritis cell-gene therapy patent covers evaluation method for consistent global production. Canada joins U.S., Japan, and China in granting protection.
💡 Novartis’ Ianalumab meets Phase III endpoints in Sjögren’s disease — NEPTUNUS-1 and NEPTUNUS-2 trials show significant disease activity reduction. Could become the first targeted therapy for this condition, with global regulatory submissions planned.
📢 Stay Ahead in Immunology Research!
✅ Like, share, and subscribe for weekly updates on immunology and autoimmune diseases
#Immunology #IBD #CrohnsDisease #UlcerativeColitis #AutoimmuneDisease #RheumatoidArthritis #SjögrensDisease #DermatologyInnovation #CellTherapy #LucidQuest #ClinicalTrials #HealthcareInnovation